55 results
8-K
EX-99
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
AEON Biopharma Reports First Quarter 2024 Financial Results
4:07pm
Predecessor
Operating expenses:
Selling, general and administrative
Research and development
Change in fair value of contingent consideration
Total operating
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
research and development (“IPR&D) “on the line” at the close of the Merger in the Successor’s opening accumulated deficit. Upon further review … and results of research and development activities, preclinical studies or clinical trials with respect to AEON’s current and potential future product
8-K
fll28762n917dy 7vl
3 May 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:27pm
8-K
4ot1yk2p1x8y0
17 Apr 24
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-99.1
91ekjqu2c1tia5kox
29 Mar 24
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
3:46pm
8-K
EX-10.1
kx8cfl9kmx2ezejp6ts
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-10.2
x6i0xoyxfv55akny4rkq
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-99.1
2qq9hipfk0yt sk0tg
13 Nov 23
AEON Biopharma Reports Third Quarter 2023 Financial Results
9:00am